3 most recent filings and news items mentioning NGNE. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/NGNE/news?limit=20"
Pull NGNE filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayNeurogene Inc. entered an underwriting agreement to sell 3.5 million shares and pre-funded warrants. The offering is intended to raise capital for general corporate purposes.
View filing at SEC.gov →Neurogene announced 30-month data showing participants significantly gained developmental milestones without plateauing or loss, demonstrating a durable therapeutic effect. This positive clinical progress for a rare disease treatment could boost investor sentiment as the company
View filing at SEC.gov →Neurogene Inc. successfully completed enrollment in its Embolden registrational trial for NGN-401, dosing 25 participants (exceeding the 20-patient target) with no safety concerns reported. Topline data is expected in the second half of 2027, potentially supporting a planned Biol
View filing at SEC.gov →